Narrow search
Showing 1 - 10 of 9,095
Cover Image
Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001-7
Lichtenberg, Frank R. - In: PharmacoEconomics 30 (2012) 3, pp. 197-211
. The effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality … replacement of older drugs by newer drugs. The effect of the vintage of chemotherapy treatments on age-adjusted cancer mortality … mortality rates, and may have accounted for as much as half of the decline. …
Persistent link: https://www.econbiz.de/10009493381
Cover Image
Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer: A Systematic Review of the Literature
GuyJr, Gery P. Guy; Ekwueme, Donatus U. - In: PharmacoEconomics 29 (2011) 10, pp. 863-874
systematically review the published literature on the YPLL and the value of productivity loss from morbidity and premature mortality … results on YPLL, eight on mortality costs and five on morbidity costs. Some studies reported results in more than one category … per death and morbidity and mortality costs. The average number of YPLL per death was approximately 15 for melanoma and 10 …
Persistent link: https://www.econbiz.de/10010614404
Cover Image
Vinorelbine in Advanced Non-Small Cell Lung Cancer: A Pharmacoeconomic Review
Coukell, Allan J.; Noble, Stuart; Faulds, Diana - In: PharmacoEconomics 15 (1999) 4, pp. 405-417
Vinorelbine is a semisynthetic vinca alkaloid that is effective against advanced non-small cell lung cancer (NSCLC). Myelosuppression is the primary dose-limiting toxicity; vinorelbine is otherwise relatively well tolerated. Two studies assessed the cost effectiveness of vinorelbine with or...
Persistent link: https://www.econbiz.de/10005590381
Cover Image
Treatment of Locally Advanced Pancreatic Carcinoma in Sweden: A Health Economic Comparison of Palliative Treatment With Best Supportive Care Versus Palliative Treatment With Gemcit...
Tennvall, Gunnel Ragnarsont; Wilking, Nils - In: PharmacoEconomics 15 (1999) 4, pp. 377-384
Objective. Patients with pancreatic cancer have only short survival after diagnosis, irrespective of treatment. The aim of this study was to perform a health economic evaluation of present standard treatment (in most cases, palliative treatment in combination with best supportive care) versus...
Persistent link: https://www.econbiz.de/10005590429
Cover Image
Decreased Medical Expenditures for Care of HIV-Seropositive Patients: The Impact of Highly Active Antiretroviral Therapy at a US Veterans Affairs Medical Center
Mole, Larry; Ockrim, Kimberly; Holodniy, Mark - In: PharmacoEconomics 16 (1999) 3, pp. 307-315
Objective: To identify any changes in expenditures and in morbidity and mortality with the progression of treatment of …, laboratory and prescription costs, and morbidity and mortality rates. Main outcome measures and results: The 3 periods had … immunosuppression (defined as CD4+ lymphocyte counts <500 cells/mm3). Morbidity and mortality were not changed by the addition of dual …
Persistent link: https://www.econbiz.de/10005590457
Cover Image
Pharmacoeconomic Considerations in Treating Patients With Acute Leukaemia
Jonsson, Viggo; Hansen, Mogen Mork; Ljungman, Per; … - In: PharmacoEconomics 15 (1999) 2, pp. 167-178
Whereas individual cost-effectiveness analyses of new agents for acute leukaemia should be performed in target populations, any meaningful pharmacoeconomic evaluation of treatment options for this condition should include the many types of costs and outcomes in unselected, representative groups...
Persistent link: https://www.econbiz.de/10005590509
Cover Image
Choice of NSAID and Management Strategy in Rheumatoid Arthritis and Osteoarthritis: The Impact on Costs and Outcomes in the UK
McCabe, Chris J.; Akehurst, Ron L.; Kirsch, Jeff; … - In: PharmacoEconomics 14 (1998) 2, pp. 191-199
justifiable in terms of the mortality and morbidity gains associated with the new lower-risk NSAIDs. …
Persistent link: https://www.econbiz.de/10005590543
Cover Image
Simvastatin After Orthotopic Heart Transplantation: Costs and Consequences
Krobot, Karl J.; Wenke, Klaus; Reichart, Bruno - In: PharmacoEconomics 15 (1999) 3, pp. 279-289
Objective: Recent data indicate that the combination of a low cholesterol diet and simvastatin following heart transplantation is associated with significant reduction of serum cholesterol levels, lower incidence of graft vessel disease (GVD) and significantly superior 4-year survival rates than...
Persistent link: https://www.econbiz.de/10005449010
Cover Image
Counting the Costs of Drug-Related Adverse Events
White, T. Jeffrey; Arakelian, Annet; Rho, Jay P. - In: PharmacoEconomics 15 (1999) 5, pp. 445-458
mortality is equally significant and has been conservatively estimated at $US30 billion dollars annually, and could exceed $US … mortality has become an increasingly important requirement for reducing healthcare expenditures. This article will review …
Persistent link: https://www.econbiz.de/10005449050
Cover Image
Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction: Economic Evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from th...
Schadlich, Peter K.; Huppertz, Eduard; Brecht, Josef Georg - In: PharmacoEconomics 14 (1998) 6, pp. 653-669
lowered rates of total mortality and rehospitalisation due to heart failure. Design and Setting: The cost …
Persistent link: https://www.econbiz.de/10005449120